Evidence map›Paper›PMID 33364273›Full record

ArticleData in brief2021

Data on selected antimalarial drug resistance markers in Zambia.

Lungowe Sitali, Mulenga C Mwenda, John M Miller, Daniel J Bridges, Moonga B Hawela, Busiku Hamainza, Mutinta Mudenda-Chilufya, Elizabeth Chizema-Kawesha, Rachel Daniels, Thomas P Eisele and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Data in brief, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Temporal genomic analysis ofmedRxiv : the preprint server for health sciences · 2024
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 3 countries.

Lungowe SitaliCentre for International Health, Faculty of Medicine, University of Bergen, Bergen, Norway.
Mulenga C MwendaPATH-Malaria Control and Elimination Partnership in Africa, National Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
John M MillerPATH-Malaria Control and Elimination Partnership in Africa, National Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Daniel J BridgesPATH-Malaria Control and Elimination Partnership in Africa, National Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Moonga B HawelaNational Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Busiku HamainzaNational Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Mutinta Mudenda-ChilufyaNational Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Elizabeth Chizema-KaweshaEnd Malaria Council, African Leaders Malaria Alliance, National Malaria Elimination Centre, Ministry of Health, Lusaka, Zambia.
Rachel DanielsBroad Institute of MIT and Harvard, Cambridge, MA, USA.
Thomas P EiseleCentre for Applied Malaria Research and Evaluation, Department of Tropical Medicine, Tulane University School of Public Health and Tropical Medicine, New Orleans, Louisiana.
Audun H NerlandDepartment of Clinical Science, Faculty of Medicine, University of Bergen, Norway.
James ChipetaSchool of Medicine and University Teaching Hospital Malaria Research Unit, University of Zambia, Lusaka, Zambia.
Bernt LindtjornCentre for International Health, Faculty of Medicine, University of Bergen, Bergen, Norway.
Ministry of Health · ZMUniversity of Bergen · NOBroad Institute · USTulane University · USUniversity Teaching Hospital · ZM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This article describes data on selected resistance markers for antimalarial drugs used in Zambia. Antimalarial drug resistance has hindered the progress in the control and elimination of malaria. Blood samples were collected during a cross-sectional household survey, conducted during the peak malaria transmission, April to May of 2017. Dried blood spots were collected during the survey and transported to a laboratory for analysis. The analysed included polymerase chain reaction (PCR) followed by high resolution melt (HRM) for mutations associated with Sulfadoxine-pyrimethamine resistance in the

Indexed as

MalariaMutationsPlasmodium falciparumSulfadoxine-pyrimethamineZambia

Identifiers

PMID33364273
PMCPMC7753129
OpenAlexW3110940773

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.